News

February 22, 2019

Olympic Champion Shannon Miller to Help Honor Ovarian Cancer Heroes

News

Olympic gymnast and ovarian cancer survivor Shannon Miller will be the keynote speaker March 15 for the second annual Ovarian Cancer Heroes event. Three individuals will be honored at ... Read more

February 20, 2019

Breast Cancer Treatments Could Be Used for Rare Ovarian Cancer, Study Suggests

News

Medications currently approved to treat some kinds of breast cancer — generally called CDK4/6 inhibitors — could be re-purposed to treat a rare type of ovarian cancer called small cell ... Read more

February 18, 2019

Phase 1 Trial Approved to Test PRGN-3005 UltraCAR-T for Advanced Platinum-resistant Ovarian Cancer

News

Precigen is preparing to launch a Phase 1 trial to test its investigational therapy PRGN-3005 UltraCAR-T for advanced, platinum-resistant ovarian cancer, after the U.S. Food and Drug Administration (FDA) cleared its ... Read more

February 15, 2019

1st Patient Dosed in Phase 1/2 Trial of COTI-2 Plus Chemo for Gynecological and Other Solid Cancers

News

A first patient has been given a combination of an investigational therapy, COTI-2, plus standard-of-care chemotherapy in an expanded Phase 1b/2a trial for gynecological and other solid tumors, Cotinga ... Read more

February 13, 2019

Lynparza Plus Weekly Chemotherapy May Help Patients with Advanced Disease, Phase 1/2 Study Finds

News

A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, ... Read more

February 11, 2019

Losartan May Improve Ovarian Cancer Treatment, Study Finds

News

Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Patients ... Read more

February 8, 2019

IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA

News

IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company ... Read more

February 6, 2019

Bavencio Shows Promise in Heavily Treated Ovarian Cancer Patients in Phase 1b Trial

News

Immune checkpoint inhibitor Bavencio (avelumab) has an acceptable safety profile and shows some anti-tumor activity among heavily pretreated ovarian cancer patients, according to a Phase 1b trial. Findings from the trial were ... Read more

February 4, 2019February 6, 2019

Phase 1 Trial Testing IMV’s Tailored Immunotherapy Doses First Ovarian Cancer Patient

News

IMV’s Phase 1 clinical trial evaluating a personalized immunotherapy that targets mutated proteins called neoepitopes in ovarian cancer patients has started dosing participants, the company announced. “The first immunization of ... Read more

February 1, 2019

Alisertib-Taxol Combo Shows Promise in Recurrent Ovarian Cancer

News

A combination of the investigational treatment alisertib and weekly Taxol (paclitaxel) showed promising anti-tumor activity in ovarian cancer patients treated in a Phase 1/2 trial, warranting further studies of the ... Read more

Pin It on Pinterest